CEO Healthcare Symposium
This event starts on Tuesday May 1st at 4:00 PM.
This YJP CEO Healthcare Symposium will convene a group of industry-leading executives, clinicians, entrepreneurs and investors to explore solutions to the most pressing problems in today's healthcare marketplace - such as reducing the time and cost of drug development, the social determinants of health and under-served populations, and achieving the triple aim of care, health, and cost - while celebrating the advancements currently being made and encouraging the healthcare leaders of tomorrow. This symposium will be a unique opportunity to candidly share knowledge and engage in innovative solutions that will stimulate positive change within the healthcare industry.
The YJP Organization is the world largest group of business leaders, executives and investors to provide mentoring leadership opportunities for the new generation of Jewish business leaders.
Adam S. Herbst, Esq., is Chief Legal, Planning and Government Relations Officer for Blythedale Children’s Hospital. He also serves as the Hospital’s Chief Compliance Officer. In this role, Mr. Herbst has legal and compliance oversight for the Hospital and is responsible for developing corporate planning strategies and administering government relations, as well as advocacy and community relations. Mr. Herbst has devoted a considerable portion of his career specializing at the intersection of where health care law meets with communications, technology and employment issues. He volunteers with several nonprofit organizations, including the New York City Police Department, Masbia Soup Kitchen, Council of Jewish Organizations of Manhattan and Flatbush and UJA. He is a frequent speaker on health care access and is an adjunct law professor at New York Law School, teaching Health Law and Policy. He has spoken at the New York City Bar Association and New York State Bar Association and is also a guest law and advocacy lecturer at many NYC hospitals. Mr. Herbst previously worked at a large Federal Health Clinic in Harlem and has extensive experience working in community health centers and health clinic operations, board governance, and regulatory matters. He has worked on issues related to housing, education, public health, economic development and has trial experience in both federal and state courts, as well as arbitrations throughout the country.
Mr. Herbst received his Juris Doctor cum laude from Albany Law School, Masters in Business Administration from Union College and his Bachelor of Arts cum laude from American University.
Presently serving as the founder and CEO of VirtualHealth, Adam has worked at the
forefront of healthcare transformation for more than a decade, perfecting the
technologies that pioneered patient-centered, value-based care. After losing a loved
one to a late stage diagnosis, Adam became passionate about improving a system that
fails to serve the highest risk populations, especially the disabled, disadvantaged, and
Under Adam's leadership, VirtualHealth has built the leading next-generation platform
for care management and population health: a cloud-native ecosystem that
incorporates clinical, behavioral, and social data streams to curate a single, complete
view of each patient. The platform then combines that whole-person view with highly
intelligent and responsive workflows ultimately enabling care teams to react to
situations in real time with optimal interventions.
Prior to starting his work in healthcare with health systems and insurance plans in the
late-2000s, Adam served as Vice President of Development and Chief Marketing Officer
for Midtown Equities and affiliates, where he oversaw $6 billion in assets. Adam
spearheaded the development of the first ever “The Ritz-Carlton Residences”, a new
concept in real estate that he co-created in partnership with The Ritz-Carlton Hotel
Adam has been recognized as the youngest person to win the Baltimore Business
Journal's “40 Under 40” award in 2006, as well as received the Daily Record’s “Most
Influential” award, the American Business Association’s “IT Executive of the Year” and
Capitol Files’ “Power Player” recognition. Adam is also a frequent speaker at healthcare
and technology events, including the annual J.P. Morgan Healthcare Conference and
Parks Associates’ Connected Health
Starting April 2018, Ms. Tanaka assumed an additional role as the Deputy Chief Executive of Corporate Planning Headquarters at Canon Inc. where she manages business development of Canon Inc. Ms. Tanaka continues to serve as the President and CEO of subsidiaries of Canon U.S.A. — Canon BioMedical, the global headquarters of Canon's biomedical business, and Canon U.S. Life Sciences, the biomedical research and development partner of Canon BioMedical. The two companies develop, manufacture, and market products that integrate Canon's technologies into novel biomedical research and medical applications.
ALAN JOSLYN, PhD
Dr. Joslyn is currently the CEO and President of Oragenics. He previously
was a co-founder of Lazarus Pharmaceuticals. Previously, in association
with Care Capital, a life sciences venture capital firm, he was Chief
Executive Officer of Sentinella Pharmaceuticals, a privately held antibiotic
company and CEO of Edusa Pharmaceuticals, a privately held
gastroenterology company. Prior to his association with Care Capital he
served as the President and Chief Executive Officer of Mt. Cook Pharma
from 2007 to 2009, and as Senior Vice President of Research & Development
at Penwest Pharmaceuticals a specialty pharmaceutical company from 2004
to 2007. From 1995 to 2004, Dr. Joslyn held a number of leadership drug
development positions within Johnson & Johnson. Before joining Johnson &
Johnson, Dr. Joslyn was engaged in gastroenterology and oncology clinical
research at Glaxo from 1988 to 1995. Dr. Joslyn also sits on the board of
Synergy Pharmaceuticals, a publically traded gastroenterology company.
Dr. Joslyn received his B.S. in Medicinal Chemistry, B.A. in Biology and
Ph.D. in Biochemical Pharmacology from the State University of New York
Dr. Zhavoronkov is the founder and CEO of Insilico Medicine, a Baltimore-based leader in the next-generation AI for drug discovery, biomarker development, and aging research. Prior to Insilico, he worked in senior roles at ATI Technologies, NeuroG Neuroinformatics, the Biogerontology Research Foundation and co-founded YLabs.AI. Since 2012 he published over 100 peer-reviewed research papers and two books. He organizes the annual Aging Forum and Artificial Intelligence for Healthcare Forum at EMBO/Basel Life in Basel. Dr. Zhavoronkov is an adjunct professor at the Buck Institute for Research on Aging.
Alina Moran is the Chief Executive Officer at NYC Health + Hospitals/
Metropolitan. Metropolitan is a 338-bed acute care facility located in East Harlem.
The hospital is member of NYC Health + Hospitals, the largest public health care
system in the nation, which provides essential services to 1.2 million New Yorkers
every year. In her current role, Mrs. Moran is responsible for leading the day-to-
day operations of the hospital, overseeing a $355 million dollar budget and over
Mrs. Moran previously served as Chief Financial Officer at NYC Health +
Hospitals/Elmhurst, where she oversaw a $570 million dollar revenue budget and
450 employees. At Elmhurst, she used Lean methodologies to significantly reduce
Discharged Not Final Billed (DNFB) and Accounts Receivable (AR) days, allowing
the hospital to capture revenue more efficiently. In addition, she served as the
Project Lead for the hospital’s implementation of EPIC, a leading electronic
medical records system. Prior to her time at Elmhurst, she served as the Assistant
Vice President of Managed Care, responsible for the negotiation, management
and implementation of the public health care system’s 18 managed care contracts
valued at $1.3 billion dollars. Over the years, she has been recognized for her
leadership in several key corporate initiatives including charge capture, revenue
optimization, documentation, and coding.
Mrs. Moran earned a Bachelor of Science in Mechanical Engineering from
Brown University and a Masters in Public Administration from Baruch College. She
is an active leader in her community and was involved in the establishment of the
Rhode Island Political Action Committee and Brown University Latino Alumni
Council. In addition, Mrs. Moran has been honored by the following prestigious
national organizations: Pew Civic Entrepreneurship Program (1998), National
Urban Fellowship Program (2000), National Hispana Leadership Institute
Executive Leadership Program (2008), America’s Essential Hospitals Fellows
Program (2013) and The Advisory Board Fellowship Program (2016). In 2017, she
was selected to serve on the Board of Trustees of New York Medical College.
Raised in the Bronx, Mrs. Moran now lives in New Jersey with her husband,
Robert, and two children.
Dr. Angelos M. Stergiou, founder, President & Chief Executive Officer of SELLAS Life Sciences Group, Inc. has held international positions of increasing responsibility in pharmaceuticals and biotechnology companies over the past 15 years, including PAION AG, Accentia Biopharmaceuticals, BioVest International, Analytica International, Anavex Life Sciences. He also co-founded a boutique NY-based health economics and pricing-reimbursement and health access company, Genesis Life Sciences (Genesis Research) prior to founding Sellas.
Dr. Stergiou has held specific roles ranging from Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Officer with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC).
Dr. Stergiou has led and overseen research endeavors in all phases of clinical development across many indications, including Central Nervous System, cardiovascular, oncology, respiratory and autoimmune diseases, and has a broad understanding of all aspects of clinical development and medical affairs. He has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. He has had numerous interactions with the FDA, EMEA and EU health authorities in addition to regulatory exposure in Australia and Japan.
Dr. Stergiou was part of the joint steering and oversight committee in the license deal of Paion’s desmoteplase drug with Forest Labs and part of senior management of Accentia Biopharmaceuticals and Biovest International. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology.
Dr. Stergiou holds a Doctor of Medicine and a Doctor of Science (honoris causa) degree from Kentucky Wesleyan College and US American Institute of Medicine, and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry.
Dr. Stergiou is a member of the Board of Trustees at Kentucky Wesleyan College and a Fellow of the Royal Society of Medicine (UK – ID:00707077), an active member of the World Medical Association, and a member of the American Academy of Physicians in Clinical Research and the Association of Clinical Research Professionals. He is a frequent guest lecturer/speaker for global clinical development and clinical research and regulatory matters, he has presented to audiences at conferences and lectured at post-secondary institutions including Columbia University, and numerous European universities.
He is fluent in English, German and Greek.
Ankit Mahadevia is the CEO of Spero Therapeutics and a member of the Board of Directors. He was formerly a Venture Partner in the life sciences group at Atlas Venture, located in Cambridge, MA. In that capacity he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, three of which he led as Acting CEO. Prior to joining Atlas in 2008, Ankit worked on product and business development with the founding team at Arcion Therapeutics. He has also held positions in business development both at Genentech and at Vanda Pharmaceuticals. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Ankit began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS).
Baiju R. Shah is Chief Executive Officer of BioMotiv and co-leader of The Harrington Project for Discovery & Development, a $300 million US and UK drug development initiative. The Project’s mission is to accelerate breakthrough discoveries into medicines. BioMotiv is the for-profit accelerator company aligned with The Project. It is advancing a portfolio of companies based on technologies licensed from top research institutions through an innovative model that efficiently aligns capital and collaborations. BioMotiv has established strategic partnerships with Takeda, Biogen, Arix Bioscience, and Charles River Laboratories.
Prior to BioMotiv, Mr. Shah was President and CEO of BioEnterprise, a partnership of Case Western Reserve University, Cleveland Clinic, Summa Health System, and University Hospitals. BioEnterprise is a business formation, recruitment and acceleration initiative that directly assists client companies in securing resources and funding to support their growth, and also serves as a catalyst for major industry initiatives such as new capital sources, translational centers, and real estate projects. During Mr. Shah’s decade-long tenure, the initiative assisted in the creation, recruitment, and acceleration of more than 110 bioscience companies in Cleveland that collectively attracted $1.3 Billion in new funding, primarily from venture capital and private equity sources. The initiative’s success has been recognized with several national awards and has helped establish the region as a recognized center of bioscience innovation.
Shah serves on the Board of Invacare (NYSE: IVC) and on the Advisory Board for Citizens Financial Group (NYSE: CFG). Prior to founding BioEnterprise, he was a consultant with McKinsey & Company, where he played a leading role in its Growth and Business Building practice. In the community, Shah currently serves on the Boards of Destination Cleveland and Global Cleveland, which he founded and Chaired. He was also the founder and Chair of Summer on the Cuyahoga and has served on the boards of several other nonprofit organizations.
Shah has been named an Ernst & Young Entrepreneur of the Year and has been recognized as one of Cleveland’s most influential leaders. He received a J.D. from Harvard Law School and a B.A. from Yale University.
Balaji Gopalan is the Co-Founder and CEO of MedStack, based in Toronto, Canada. A 15 year technology veteran, Balaji has built a specialization and focus on platform strategies, in which companies share technology assets to build more powerful, innovative and transformative solutions. He has taken this strategy, along with his extensive experience teaching and mentoring on product strategy and entrepreneurship to build MedStack, a company that helps innovators in healthcare get to market faster via platform tools. MedStack services healthcare startups globally and is a graduate of Dreamit Health and 500 Startups.
Barrett Bready, M.D., is Founder and CEO at Nabsys. Dr. Bready is an adjunct professor at Brown University where he teaches Biotechnology Management. He serves as a commissioner of the I-195 Redevelopment District Commission, a large land redevelopment project in downtown Providence with a focus on life sciences and other high technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year from Providence Business News. Dr. Bready received an M.D. and an Sc.B. in physics from Brown University, both as part of Brown’s Program in Liberal Medical Education (PLME).
As President and Chief Executive Officer of Einstein Healthcare Network for the last 13 years, Barry Freedman has led the organization through a time of unprecedented change and growth. He has overseen the network’s expansion into a more than $1 billion enterprise, with more than 8,500 employees, 450 residents and fellows, and more than 1,200 employed and independent physicians. Freedman joined Einstein in 2003.
A few of the network’s major accomplishments achieved during Freedman’s tenure include:
The 2012 opening of Einstein Medical Center Montgomery, the first completely new hospital built in southeastern Pennsylvania in more than a decade.
The 2005 addition of Einstein Medical Center Elkins Park to the network. The facility is now the home of MossRehab, ranked as the top rehabilitation hospital in Pennsylvania and #8 in the nation by U.S. News & World Report for 22 years.
The expanded geographic reach of Einstein’s ambulatory care network with the opening of new outpatients centers in locations such as Collegeville, Pa., and Holmesburg, Pa.
At a time when many hospitals in the region are closing their maternity wards, the deepening of Einstein’s commitment to women and babies with the expansion of the network’s OB/GYN services and an increase in births from about 2,000 per year to 5,000 annually.
The development of regional service lines in areas such as Bariatrics, CT Surgery, Orthopedics and Neonatology that cover the network’s entire service area and have helped to position Einstein as a provider of choice in the region.
The relaunch of the Einstein brand, which provided the organization with a powerful tool to raise consumer awareness, unify the different entities and send a message to patients that they can expect to receive the same level of compassionate, high-quality care throughout the network.
The launch of The Einstein Campaign, the largest multi-year, fund-raising initiative in the history of the network, which expects to raise $150 million by 2016.
Prior to joining Einstein, Freedman was the President and CEO of Mount Sinai Hospital in New York City.
Freedman is a recognized leader in health affairs at the local, state and national level. He is past-Chairman of the Board of the Greater New York Hospital Association and has served as Chairman of the Board of the League of Voluntary Hospitals of New York, and Lead Director of the Board of the Premier Hospitals Alliance. Currently, Mr. Freedman serves on the Boards of the Delaware Valley Health Council, The Hospital & Healthsystem Association of Pennsylvania, Health Partners, and is a member of the Healthcare Institute.
Freedman was recognized by Philadelphia Business Journal’s Healthcare Innovation Awards as CEO of the Year in 2012. In November 2014, he was once again named to Becker’s Hospital Review’s list of the top 130 Non-Profit Hospital and Health System CEOs to Know.
William “Bill” Enright joined Altimmune (formerly known as Vaxin) in June 2008 and currently serves as President and CEO. Prior to joining Altimmune, Mr. Enright spent six years with GenVec, Inc. with increasing responsibilities including the Head of Business Development. Mr. Enright was responsible for helping to build GenVec’s vaccine business including approximately $140M of funding for vaccine related initiatives and moving four vaccines into clinical development. Mr. Enright brings more than 24 years of experience in a variety of positions within the life science and biotech industries. Mr. Enright was a self-employed consultant, where he provided business development and strategic marketing services to academic institutions, and a number of small to mid-size life science companies. Prior to becoming a consultant, and after spending several years as a bench scientist at SUNY at Buffalo, Mr. Enright spent 12 years with Life Technologies, Inc., working in various licensing, business management, manufacturing and research roles. Mr. Enright received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.
Bob Terbrueggen, Ph.D., is the Founder and CEO of DxTerity, a Los Angeles based genomics company. Powered by its DxCollect® Fingerstick Collection kit and DxDirect® Genomics Platform, DxTerity is demonstrating how frequent, from home, RNA monitoring can improve the management of chronic autoimmune diseases like Lupus and Multiple Sclerosis.
Prior to founding DxTerity, Bob was Director of R&D at Clinical MicroSensors which was purchased by Motorola for $300 million in 2002. Bob subsequently co-founded NanoBiomics which was named the 2005 best start-up of the year by the Arizona Biotech Association and later acquired by the Molecular Profiling Institute.
Bob received his Ph.D. in Chemistry from the California Institute of Technology, and his BS in Chemistry and Molecular Biology for the University of Michigan. Bob is an inventor on 21 approved U.S. patents.
Bozidar Jovicevic MD/MBA,
VP Global Head of Digital Medicine at Sanofi
Bozidar Jovicevic is a Global Head of Digital Medicines at Sanofi, in charge for beyond-the-drug initiatives. He is MD/MBA by training and during the first part of his career he spent 12 years at Novartis in various sales and marketing roles, launching two multi-billion dollar products on a regional and global level. He then moved to a medical function where he orchestrated transformation of multichannel engagement with HCPs through building a global eCongress platform dubbed as “Netflix of medical conferences” (currently available in 104 countries).
Bozidar is highly entrepreneurial (founded three startups), loves playing chess (used to play semi-professionally) and is passionate about the science of human behavior and peak performance.
Christopher J. Schaber, PhD has over 28 years experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been Soligenix's President and Chief Executive Officer and a director since August 2006. He also served on the board of directors for the Alliance for BioSecurity and for the Biotechnology Council of NJ (BioNJ). He has been a member of the corporate councils for both the National Organization for Rare Disorders (NORD) and the American Society for Blood and Marrow Transplantation (ASBMT). Prior to joining the company, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, he was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, he was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his BA from Western Maryland College, his MS in Pharmaceutics from Temple University School of Pharmacy and his PhD in Pharmaceutical Sciences from the Union Graduate School. During his career, Dr. Schaber has played a significant role in raising in excess of $200 million through both public offerings and private placements, as well as over $70 million through the achievement of government grant and contract awards.
Dr. Granowitz joined Amarin in January 2016 with extensive experience managing a multi-national medical affairs organization for a portfolio of leading cardiovascular products. Prior to joining Amarin, Dr. Granowitz was senior vice president and head of global medical affairs, global human health at Merck, where he developed and implemented an entirely new global medical affairs organization following Merck’s merger with Schering-Plough. In this capacity, among his numerous achievements, he provided critical medical affairs support in the run-up to and read-out of Merck’s cardiovascular outcomes study, IMPROVE-IT. From 2003 to 2008, he was group vice president, head of global medical affairs for Schering-Plough.
Dr. Granowitz has been elected to serve on the Board of Directors of the New York City American Heart Association starting in June, 2017. Dr. Granowitz currently serves as a volunteer on the boards of directors of several organizations including the Columbia College of Physicians and Surgeons, the Rabbinical College of America and the American Associates of Ben Gurion University.
Mr. King has served as Chairman of the Board, President, and Chief Executive Officer of the Company since May 6, 2009; prior to that date he served as a director, President and Chief Executive Officer of the Company since January 1, 2007. Mr. King served as Executive Vice President and Chief Operating Officer from December 2005 to January 2007, as Executive Vice President of Strategic Planning and Corporate Development from January 2004 to December 2005 and was hired in September 2001 as Senior Vice President, General Counsel and Chief Compliance Officer. Prior to joining the Company, he was a partner with Hogan & Hartson LLP (now Hogan Lovells US LLP) in Baltimore, Maryland from 1992 to 2001. Mr. King was appointed to the Board of Directors of Cardinal Health, Inc. in 2011 and chairs its Human Resources and Compensation Committee. He also sits on the Boards of Directors of the Seattle Science Foundation, PATH, Inc., and the American Clinical Laboratory Association. He is also on the Board of Trustees of Elon University and Durham Academy. Mr. King has over eleven years’ experience with the Company in a variety of roles of increasing responsibility in corporate operations, strategic planning, and corporate administration. Mr. King has a deep understanding of the clinical laboratory industry, business strategy, sales and marketing and executive management of the Company and its operations.
David Lundquist is an accomplished and solutions-focused Senior Executive with 35 years of
experience across the healthcare industry. Leveraging extensive experience restructuring companies to
drive value, he is skilled in developing strategic vision and achieving turnaround results following
periods of stagnant or declining performance. His broad areas of expertise include strategic planning,
change management, business development, project and program management, process
improvements, and cross-functional team building and leadership.
Throughout his executive career, David has held leadership positions at medical and health care
organizations in Oklahoma, New Jersey, and New York. He currently is President/CEO for Rome
Memorial Hospital and its affiliates in Rome, New York. He has been responsible for establishing a
new strategic vision for a hospital experiencing several years of declining operating performance,
increasing market share, developing key strategic affiliation partnerships, and building a strong
leadership team to drive organizational success; achieving $14M in cost savings for an alliance of
several hospitals through implementation of a collaborative clinical environment to eliminate
inefficiencies; and facilitating the restructure, turnaround, and acquisition of a health system
experiencing previous losses of over $80M, ultimately positioning the organization as a healthcare
leader in the region.
David holds a BS in Industrial Engineering from the University of Oklahoma and an MBA from the
Meinders School of Business at Oklahoma City University. An experienced Board Member, he has
held numerous Board positions with community-based organizations.
David A. Sinclair, Ph.D. is an entrepreneur and world leader in aging research. He is a
tenured Professor of Genetics at Harvard Medical School, co-Director of the Paul F.
Glenn Center for the Biological Mechanisms of Aging, Professor and Head of the Aging
Labs at UNSW, Sydney, and an honorary Professor at the University of Sydney. He is
best known for his work on genes and small molecules that delay aging, including the
Sirtuin genes, resveratrol and NAD precursors. He has published over 160 scientific
papers, is a co-inventor on over 50 patents, and has co-founded 12 biotechnology
companies in the areas of aging, vaccines, diabetes, fertility, cancer, and biodefense. He
serves as co-chief editor of the scientific journal Aging, works with national defense
agencies and with NASA. He has received 35 honors including being one of Australia's
leading scientists under 45, the CSL prize, an Advance Global Australian Award, an
ASMR Medal, the NIH Director’s Pioneer award, TIME magazine’s list of the “100 most
influential people in the world” and a Member of the Order of Australia in 2018.
Davis Farmer is a seasoned entrepreneur in the biomedical industry. He has formed a dozen companies
as a principal, investor and/or CEO and consummated numerous transactions for companies and on
behalf of academic research institutions. His start-up activities have taken place in the US, the UK,
Russia and Austral-Asia, where he co-managed the first venture fund in New Zealand. His deal portfolio
includes transactions in Japan, China, the US, Europe and New Zealand. The bulk of his work has
focused on technology with an emphasis on the immune response.
Davis currently serves as Chairman of MSM Protein Technologies and Founder and Partner of the
Ulysses Advisory Group, both based in Boston.
Donald Levick, MD, MBA, CPE, FHIMSS is a practicing Pediatrician and the Chief Medical Information Officer at Lehigh Valley Health Network (LVHN). He has worked in Clinical Informatics since 2000, and has worked on numerous healthcare information technology projects. He was one of the executive clinical leaders for the implementation of Epic at LVHN. He is Chair of the Network Data Governance Committee and was the initial lead for the Enterprise Analytics Group, the network resource for reports and analytics. He is the Past-President of the Medical Staff of LVHN and currently serves as Treasurer for the LVHN Medical Staff.
Dr. Levick holds a BA from LaSalle University; received his MD from the Medical College of Pennsylvania (now Drexel College of Medicine), and did his pediatric training at St. Christopher’s Hospital for Chidlren. He received his MBA from University of Phoenix. He is board certified in Pediatrics and was in the first cohort to be board certified in Clinical Informatics. Dr. Levick received his CPE (Certified Physician Executive) through the American Association for Physician Leadership.
Dr. Levick is a HIMSS Fellow and served on the Board of Delaware Valley HIMSS from 2005 to 2014. He is the past-Chair of the Mid-Atlantic Chapter of The American Medical Informatics Association (AMIA).
He was the Principal Investigator for a $1.2M AHRQ grant studying the outcomes of the implementation of a perinatal continuum of care information system, and is a co-author of the 2012 HIMSS publication and HIMSS Book of the Year, “Improving Outcomes with Clinical Decision Support, An Implementer’s Guide.” He has been published in peer reviewed journals and has spoken regionally and nationally on clinical decision support, large scale change, data governance, and emerging technology.
He has been married for 34 years and his wife is a practicing pediatrician. They have three children, all of whom are out of the house and off the books.
Dr. Elizabeth Garner has served as our Senior Vice President and Chief Medical Officer since January 2014. Previously, she served as Vice President, Medical Affairs, Women's Health and Preventive Care at Myriad Genetics Laboratories from 2012 to 2014. From 2011 to 2012, she was Senior Medical Director, Women's Health at Abbott Laboratories where she served as the Clinical Lead, Endometriosis Program. Prior to that, Dr. Garner served as Associate Director and then Director, Vaccines Clinical Research at Merck Research Laboratories from 2007 to 2011. Dr. Garner received joint M.D. and M.P.H degrees from Harvard Medical School and the School of Public Health. She completed her residency in obstetrics and gynecology at Brigham and Women's/Massachusetts General Hospitals; her subspecialty fellowship in gynecologic oncology at Brigham and Women's and the Dana-Farber Cancer Institute; and received board certification in both general Obstetrics and Gynecology and Gynecologic Oncology. Prior to entering the pharmaceutical industry, she had several years of experience in academic clinical practice, research and teaching at Harvard Medical School. Dr. Garner is a member of the Board of Directors for the American Medical Women’s Association.
Eric Elenko, PhD, is the Chief of Research and Strategy at PureTech Health where he has led the development of a number of programs, including Akili Interactive Labs, Gelesis, Karuna Pharmaceuticals and Sonde Health. Prior to joining PureTech Health, Dr. Elenko was a consultant with McKinsey and Company where he advised senior executives of both Fortune 500 and specialty pharmaceutical companies on a range of issues such as product licensing, mergers and acquisitions, research and development strategy and marketing. Dr. Elenko received his BA in Biology from Swarthmore College and his PhD in Biomedical Sciences from University of California, San Diego.
Eric Harness has been involved with the formation of the citizen science space BioCurious since its inception. He was elected to the position of President. With the help of cadery of volenteers and leadership team he has helped to propel BioCurious to its most profitable year since their inception and doubling its space and capablities Eric has also represented BioCurious at the Obama White House during formation of the Nation of Makers as well as the Sustainable Development Goals Innovation meeting at the United Nations. He has worked to procure much of the equipment, supplies, and has taught many of the initial classes and seminars including PCR, cloning, and basic microbiology. He has been instrumental in the development of the safety policy at BioCurious in addition to advising on policy and ethics for the greater Citizen Scientist community. Eric has aided many other Citizen Scientist labs by providing guidance to help safely run, organize and grow their maker spaces. His work at BioCurious continues as President and leading the microfluidics, and cuttlefish community projects as they settle into their new location in Santa Clara, California.
Frank Reynolds, MBA/MSE/MS
Chairman of the Board, CEO, CFO, CSO & Co-Founder
Frank co-invented NeuroRelease (NR14), a non-opiate, non-addictive morphine replacement for post -surgical pain. Three-day, seven-day, treatment formulations are in development as FDA approval is expected for NeuroRelease 14 day in late 2019.
Frank also co-invented the NeuroScaffold™, the first treatment to restore function in humans after a traumatic spinal cord injury. In 2014, the National Spinal Injury Association awarded Frank a life-time achievement award for inventing the NeuroScaffold and first successful SCI treatment to work in humans.
Since 2005, Frank is one of the most inventive CEO’s in Pharma. He is a co-inventor on over 100 biomaterials based and neurologically focused patent applications. His research has been published in the Journal of Biomaterials and the Journal of Neuroscience: Methods.
Mr. Reynolds was featured in the March 2010 and October 2009 issues of Inc. Magazine. He was awarded the 2010 Irish Life Science 50 Award by the President of Ireland, Mary McAleese. Mr. Reynolds won the American Spinal Injury Association’s “2011 David F Apple Award for Excellence in Publishing” in spinal cord injury rehabilitation research.
Frank Reynolds founded PixarBio Corporation (OTC: PXRB) to invent, research and develop biologics, drugs, and devices for a range a neurological conditions. Since September 2013, pain, spinal cord injury, epilepsy, and Parkinson’s disease have been a prime focus of his research. As a neuroscientist, engineer and entrepreneur Frank invents and patents his own neurological treatments and he recruits the teams to commercialize his IP portfolio.
Frank has one of the most unique CEO skillsets in Pharma based on relevant education and subject matter expertise resulting in core competencies to succeed in the Neuro-Pharma industry.
Frank’s competencies in neuroscience, neurosurgery, drug discovery, drug delivery, US FDA Regulatory Affairs, Clinical Studies, cGMP Manufacturing, Patents, Intellectual Property, FASB, SEC, Financial Analysis, MIS, HR, Process Engineering, all combined led to breakthroughs for paralyzing spinal cord injury, the NeuroScaffold™ and people in pain
Frank won the IABCN 2015 “Taoiseach Award” or Prime Minister’s Award for Leadership, presented by Anne Anderson, Ireland Ambassador to the USA.
Formal education at MIT, Harvard, Wharton, Univ. of Penn Engineering, St. Joseph’s, Temple University, Chestnut Hill College, Rider University and other leading universities provided Frank with required formal education to develop new treatments for neurological disease. Frank serves on the Board of Directors of Chestnut Hill College.
Frank founded InVivo Therapeutics in 2005, and took the company public as InVivo Therapeutics Holdings Corporation (NASD: NVIV) in October 2010. Frank served as Chairman of the Board, CEO and CFO until August 2013. Under his leadership, InVivo’s market cap reached $520M.
• Won 2013 and “2016 Best Places to Work” Boston Business Journal
• Received the Irish Education 100 Award 2017
• Nominated for the “2013 Boston Business Journal CFO of the Year”
• Led InVivo Therapeutics to win the Boston Business Journal’s “2013 Best Places to Work in Boston”.
Relevant Corporate Governance
Executive Board Member of the Irish American Business Chamber
Board of the Special Olympics of Massachusetts (Retired)
Research Member, College of Neurosurgeons
Member, American Institute of CPA’s
Member of the American College of Healthcare Executives
Member of the American Psychological Association
Chairman of the Board, InVivo Therapeutics Corp (NASD:NVIV)
Chairman of the Board, PixarBio Corporation (OTC:PXRB)
Board of Directors, Chestnut Hill College
Frank has over 35 years of management experience and was the founder and CEO of Expand The Knowledge, Inc. an IT Consulting firm to the financial and pharma sector.
Dr. Guanghui Hu is the President and CEO of Admera Health. Previously, Dr. Hu served as Vice President and Global Business Leader of Translational Genomics at GENEWIZ, Inc. Prior to joining GENEWIZ, Inc., Dr. Hu acquired over 12 years of drug development and management experience in the pharmaceutical industry at companies including Merck and GlaxoSmithKline. Dr. Hu completed postdoctoral research at the University of California Los Angeles after earning his Ph.D. from Baylor College of Medicine, holds a Master of Science degree from the Chinese Academy of Sciences, and a Bachelor of Science degree from Tsinghua University.
Visionary executive with extensive experience at the Board, CEO, and COO level. Repeated success
driving double- and triple-digit revenue gains for complex, multinational businesses. Background
includes guiding companies through periods of notable change, including rapid growth, repositioning,
turnarounds, and rightsizing.
Execution focused Leader with a track record of significantly growing companies, leveraging cross
functional skills - strategy, finance, marketing and operations.
Himmat joined the Circle of Life Home Care Companies in Jan 2017 to help propel the firm to the next
level of growth and evolution. Prior to this role, Himmat was a CEO of a Chemicals Company, CIO of an
Integrated $300 million Sales Manufacturing Firm, Director Strategy & Business Development for a
Software firm built through strategic acquisitions, and a VP, Corporate Finance of a $15 billion Real
In a turnaround experience, Himmat grew an effectively bankrupt firm and almost doubled sales in less
than a year by focusing on the basics and ensuring his employees and customers interests were aligned.
His management skills have evolved from the variety of roles in his career and above all, he believes
satisfied stakeholders, particularly motivated employees, and delighted customers, help make good
Himmat received a BBA degree from The George Washington University in Finance and a MBA degree in
Entrepreneurial Management from The Wharton School, University of Pennsylvania.
Holly Chaffee, MSN,BSN, RN serves as the President/CEO of VNA Care, a subsidiary of Atrius Health serving more than 50,000 patients a year as Massachusetts largest non –profit home health and Hospice provider. With more than 30 years of experience in healthcare, Holly has distinguished herself as an innovator in enhancing the quality of patient care industry-wide. This includes her advocacy and work with VNA’s to set strong clinical standards. Chaffee was recognized as a 2017 Healthcare Hero by the publication Business West & Healthcare News, specifically earning the honor as the Health/Wellness Administrator of the year. Her innovative work and use of up to date technology has been nationally recognized after she addressed healthcare leaders across the country. Holly is the Chair of the Board for Home Care Alliance the Massachusetts Home Care Trade organization. Her Commitment to quality has been recognized when she led organizations to 5 stars and has attained deficiency free surveys with the MA Department of Public Health and Home Care Elite® Awards of Excellence.
Mr. Smith has been the Chief Financial Officer for Rhythm Pharmaceuticals since August 2017. He brings over 20 years of global finance and management experience across multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. He joins Rhythm from Celgene Corporation, where he served as Vice President, Finance and Chief Financial Officer of the Company’s Inflammation and Immunology Business Unit. In this role, Mr. Smith provided finance leadership for the global launch of Otezla®, co-led the integration of Receptos, Inc. following its acquisition by Celgene, and led global business planning and analysis for commercial affiliates and clinical study activities in over 16 countries. Before joining Celgene, Mr. Smith worked in roles of increasing responsibility at Bunge Limited, including Director of Investor Relations, Chief Financial Officer–Asia, Corporate Treasurer, and Chief Financial Officer of Bunge’s Sugar and Bioenergy Segment. He holds an M.B.A. in Finance from NYU’s Stern School of Business and a B.A. in History, with honors, from Northwestern University. Mr. Smith also serves as an Independent Director of Genessee & Wyoming Inc. and is a member of the Compensation Committee.
Ilan Danieli has served as Precipio's CEO since founding the company in
2011. With over 20 years managing small and medium-size companies,
some of his previous experiences include COO of Osiris, a publicly-traded
company based in New York City with operations in the US, Canada,
Europe; and VP of Operation at Laurus Capital Management, a multi-billion
dollar hedge fund; as well as in various other entrepreneurial ventures. Ilan
holds an MBA from the Darden School at the University of Virginia, and a
BA in Economics from Bar-Ilan University in Israel, and served in the Israeli
military as a tank commander. He is also a private pilot, and while on the
ground, he enjoys travel, scuba diving, skiing (snow and water), and also
dabbles in gourmet cooking.
Dr. James Tsai is President of New York Eye and Ear Infirmary of Mount Sinai, the nation’s first
and longest operating specialty hospital. He also serves as the Delafield-Rodgers Professor of
Ophthalmology at the Icahn School of Medicine at Mount Sinai and System Chair of
Ophthalmology for the Mount Sinai Health System. A clinician-scientist and experienced health
care administrator, Tsai also serves as Chair of the Glaucoma Subcommittee of the National Eye
Health Education Program Planning Committee of the National Institutes of Health (NIH),
Associate Examiner for the American Board of Ophthalmology, and Treasurer of the
International Joint Commission on Allied Health Personnel in Ophthalmology.
A Magna Cum Laude graduate of Amherst College, Tsai earned his Medical Degree from
Stanford University School of Medicine and his MBA from Vanderbilt University. He completed
his residency in ophthalmology at the Doheny Eye Institute, which at the time was affiliated with
the University of Southern California, Los Angeles. Tsai received his glaucoma fellowship
training at the Bascom Palmer Eye Institute, University of Miami Health System, and at
Moorfields Eye Hospital and the Institute of Ophthalmology in London.
Dr. Kamens is the Executive Director of Addgene, a mission driven, nonprofit dedicated to helping scientists around the world share useful research reagents and data. According to the Boston Globe, Addgene is the #1 2016 Boston Globe Top Place to Work and has won numerous other business and employee honors. She received her PhD in Genetics from Harvard Medical School then spent 20 years as a researcher and director in pharma and biotech. Dr. Kamens founded the Boston chapter of the Association for Women in Science. She is active in creating and supporting a number of mentoring programs for science trainees. In Dr. Kamens was named one of PharmaVoice's 100 Most Inspiring Commanders & Chiefs. Joanne gives over 80 talks each year on career topics all over the world. She speaks widely to science and tech trainees, women in science groups and to pharma teams on topics such as Winning Company Culture, Implicit Bias, Management 101, Making the most of Mentoring Relationships, Work/Life Negotiation, Not Networking - Building Relationships for Success.You can find her @jkamens on Twitter and on Linked In https://www.linkedin.com/in/joannekamens.
John Hui is a serial entrepreneur and accredited angel investor in the healthcare industry. His sales, marketing and entrepreneurial experiences cover industry sectors of healthcare technology, clinical laboratory, diagnostic imaging, medical devices, pharmaceuticals, and medical tourism. His angel investment portfolio focuses on healthcare IT and medical diagnostic companies.
John is a Co-Founder and Head of Strategy for Twiage, an award-winning mobile healthcare IT startup company that provides a novel pre-hospital triage and care coordination platform enabling hospitals and EMS to accelerate life-saving care. John has also been co-founders of Reliant Diagnostics, a radiology management company and Superus Health, an international healthcare consultancy. Prior to starting his own business, John has been an accomplished sales executive with Fortune 500 companies, such as LabCorp, Abbott and Schering-Plough.
John received his MBA from the Johnson Graduate School of Management at Cornell University as a Fellow of the Entrepreneurship and Innovation Institute. He holds his BBA in Advertising from the Zicklin School of Business at Baruch College. He is the Chair of ACHE New Jersey Chapter’s Distinguish Service Award Committee and a member of Angel Capital Association’s Collaboration Committee.
Mr. Fleming is currently the President and CEO of Q-State Biosciences, an early stage privately funded neuroscience company in Cambridge MA. Q-State uses its proprietary technology platform to enable the discovery of new medicines for diseases such as ALS, epilepsy, Parkinson’s Disease and neuropathic pain. Since 1996, Mr. Fleming has been the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, which raised over $1 billion in early stage capital resulting in 21 IPOs and over 40 M&A transactions. During his career Mr. Fleming co-founded several neuroscience companies that were later acquired including Synaptic Pharmaceuticals (acquired by Lundbeck); Memory Pharmaceuticals (acquired by Roche); and Hypnion Pharmaceuticals (acquired by Lilly).
Mr. Fleming has been a life science entrepreneur for more than 31 years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining Oxford Bioscience Partners in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage health care and biotechnology companies in Israel, and the Korea Seoul Life Science Fund, based in Seoul, Korea.
Mr. Fleming is a director of Leerink Partners, a Boston based investment bank specializing in health care companies, and several other private early stage biotechnology companies. He is the Chairman of the Board of the regions only commercial shellfish hatchery, Aquaculture Research Corporation.
Mr. Fleming also is a board member of several nonprofit organizations including: The Institute for Pediatric Innovation, Rim Power and the Network for Excellence in Health Innovation (NEHI).
Mr. Fleming has been a Senior Lecturer at the MIT Sloan School of Management since 2002, where he co-teaches a class on business strategy for life science managers. He holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor’s degree in Political Science from the University of California, Berkeley.
Physician-scientist and cancer immunotherapy drug developer with over 15 years of leadership experience in clinical oncology research in academia/industry as well as leadership of basic science and translational research programs. Experienced as leader of a wide variety of organizational structures including research programs in government, highly-matrixed early and late-stage global clinical development teams in large pharma and biotech sectors, international scientific organizations, partnered joint development committees (US/ex-US) and various boards/committees.
Specialties: Immuno-Oncology, Oncology, Hematology, Drug Development (small molecules, biologics, vaccines, etc.), Tumor Biology/Tumor Immunology, Cancer Immunotherapy, PD-1, PD-L1, Nivolumab, Ipilimumab, KIR, CD137, DART, Bispecifics, Clinical Research, Combination Therapy, Apoptosis.
Dr. Stauffer is the Chief Medical Officer (CMO) of CARA Therapeutics, a public biotech firm in Stamford, CT. He is also the Principal and Founder of Alta Life Sciences, LLC., a boutique pharmaceutical/investment consulting firm based in Princeton, NJ. Since 2004 he has served as CMO in both public and private specialty pharma/biotech companies. From 2004-2009 he was CMO at Alpharma Pharmaceuticals; and the architect of the clinical development program for EMBEDA, the first abuse-deterrent long-acting opioid analgesic approved by the FDA. His medical practice and clinical research/medical affairs experience spans over 20 years; having built teams of clinicians, scientists, MSLs, regulators and safety experts in support of clinical development projects, marketed brand drugs and devices. He was instrumental in raising CARA’s secondary offerings, resulting in $80M and $92M of new equity financing in 2015 and 2017 respectively.
He practiced clinically for eight years, first as a Navy general medicine physician and then as an Anesthesiologist. He completed residency training in Anesthesiology & Critical Care Medicine at the Johns Hopkins University Hospital and maintained an appointment as part-time Assistant Professor in the Department of Anesthesiology and Critical Care Medicine at the Johns Hopkins University School of Medicine through 2016. He received his MBA from a joint program (TRIUM) between New York University, Stern School of Business, London School of Economics (LSE) and HEC (Hautes Etudes Commerciales) School of Management in Paris. Dr. Stauffer is a veteran of the US Navy; honorably discharged as a Lieutenant Commander after serving 10 years, including a 3-yr.active duty/5-yr. active reserve tour as a Naval Medical Officer. He maintains an active Pennsylvania physician medical license.
Joe began his industry career as Global Medical Director at Abbott Laboratories. In that role he was responsible for Phase I-III trials and medical affiars support of hospital and retail marketed products. Prior to Abbott he worked at FDA as a Medical Review Officer in the Anti-Inflammatory & Analgesic Division of the Center for Drug Evaluation and Research. He led clinical, regulatory and medical affairs teams at Alpharma and Ikaria; both of which were acquired in $1.6B cash deals in 2009 and 2014 respectively.
He is a 2002 founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT). In 2011, under the FDA’s Critical Path Initiative, this collaboration became an official public-private partnership between pharma, FDA, NIH, academia and patient advocacy associations. The new group, Analgesic Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) is an ongoing multi-year effort designed to address the major gaps in scientific information which confound analgesic clinical trials and analgesic drug development. He has lectured internationally on topics ranging from clinical drug development, medical affairs, investor relations and the FDA regulatory process.
In 2005 he served as an expert member of the FDA/Mayo Clinic Working group on Patient Reported Outcomes and co-authored the supportive paper (Value in Health, Nov/Dec 2007) on validation of self-reported outcome measures. This consortium presented their consensus to the FDA at an open meeting in February 2006 as part of the rollout of the FDA Guidance for Industry, Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.
He has served as an expert manuscript reviewer for Mayo Clinic Proceedings (2006) , Pain Medicine (2014), and Therapeutic Advances in Drug Therapy (2014) In 2007 he was named one of the “100 Most Inspiring People” by PharmaVOICE magazine. In 2011 he was selected as a Board member of the American Academy of Pain Medicine Foundation. From 2014-2015 he served on the Board of Directors of TrialScope, a provider of technology enhanced clinical trial solutions and services. Since 2015 he has served in the Director Network of Edison Partners, a growth equity firm based in Princeton, NJ.
In 2012 the European Commission appointed him as an expert clinical research reviewer as part of the European Union (EU) health initiative for Research & Innovation. He was invited back in 2014 to continue this work for the EU 'Health, Demographic Change and Wellbeing' Horizon 2020 project.
Justin Li is currently a partner at J&J Investments Worldwide Ltd., an angel investment firm focused on healthcare technologies. Through J&J, Justin works in an operational capacity as the General Manager for Laboratory for Advanced Medicine, Inc. (LAM), where he heads up therapeutics research & development efforts, overall financing strategy, and contributes to the strategic direction and sales of LAM’s flagship methylation based cancer diagnostic product. Prior to his role with LAM, Justin was the Regional Consulting Manager for FactSet Research System Inc.’s Los Angeles office, a 10,000+ person company providing advanced portfolio management and quantitative analytics solutions for institutional investors. At FactSet, Justin managed a $30MM business consulting top decile institutional investors and led the company’s expansion into Southern California. Justin has also spent time directly on the derivatives trading desk at Phillips 66 commercial division, where he held a Market Analysis / Hedge Trading position and conducted fundamental analysis on spot and futures markets for various oil products, as well as executing contracts on the NYMEX to decrease the refinery’s price exposure. Justin completed his B.S.B.A. in Finance at University of Colorado at Boulder. He is a CFA charterholder.
Vice-President/Executive Director, Cardiovascular Services, Yale-New Haven Health System
Kevin Conroy was appointed president and CEO for Exact Sciences in 2009. He was named chairman of the board in 2014. Under Mr. Conroy’s leadership, the company has grown from three individuals to a team of more than 1,300 employees committed to detecting cancer earlier. During his tenure at Exact Sciences, Mr. Conroy established an ongoing partnership with Mayo Clinic to identify the earliest possible cancer-related changes in DNA and develop highly sensitive, specific and reliable diagnostic tools. This collaboration led to the development of Cologuard, a proprietary multi-marker test for the early detection of colorectal cancer. Cologuard was approved by the FDA and covered by Medicare in 2014 and is a recommended screening method by the leading colorectal cancer screening guidelines.
Before joining Exact Sciences, Mr. Conroy served as president and CEO for Third Wave Technologies, a molecular diagnostics company, where he led the development of innovative DNA and RNA analysis products. He also held leadership positions at GE Healthcare.
Mr. Conroy serves as a director of the biopharmaceutical company Epizyme, Inc. (Nasdaq: EPZM). He is also a director of the Greater Madison Chamber of Commerce and serves on the University of Wisconsin–Madison Chancellor’s Advisory Council. Additionally, he has served many leading non-profit and community organizations, including Bioforward, Wisconsin Technology Council, United Way, Urban League and Badger Advocates.
A native of Michigan, Mr. Conroy earned his Juris Doctorate from University of Michigan Law School and holds a Bachelor of Science degree from Michigan State University.
Kevin Rakin is co-founder of HighCape Partners and brings more than 25 years of experience as an executive and investor in the life sciences industry. He most recently served as President of Shire Regenerative Medicine. Prior to joining Shire, Mr. Rakin was Chairman and Chief Executive Officer of Advanced BioHealing from 2007 until its acquisition by Shire in 2011 for $750M. Before that, he served as an executive-in- residence at Canaan Partners. Previously, he was a Co-Founder, President and Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a publicly traded pharmacogenomics company, until its merger with Clinical Data, Inc. in 2005. His Boar memberships include Aziyo Biologics, Inc. (Chairman), Cheetah Medical, Inc. (Chairman), Cybrexa, Inc., and TELA Bio, Inc., as well as Histogenics Corp. and Collagen Matrix, Inc.
He has previously served as a Board member for Ipsogen SA, Vion Pharmaceuticals, Inc., OMRIX Biopharmaceuticals, Inc., and Clinical Data, Inc. Mr. Rakin received an M.B.A. from Columbia University and B.Com and B.Com (Hons) degrees from the University of Cape Town, South Africa.
Krish Krishnan is an accomplished biotech executive. He was specifically involved in two successful IPOs (COO/CFO of New River Pharmaceuticals, Inc., NASDAQ: NRPH) and COO of Intrexon Corporation, Inc., NYSE:XON), approval of the blockbuster drug Vyvanse (for ADHD in 2007) and the sale of New River Pharmaceuticals, Inc. to Shire Pharmaceuticals, plc for $2.6 billion. He served as the CEO of Pinnacle Pharmaceuticals, Inc. and advanced a potential treatment for urinary tract infection from discovery to Phase II. He has served as Board member for Biotie Therapies Oyi (BTH1V:Helsinki, NASDAQ: BITI), a specialized drug development company in Finland and Thar Pharmaceuticals,Inc. prior to its sale to Grunenthal GmbH in 2017.
Krish started his career as a Senior Engineer at E.I.Dupont de Nemours. Krish has an undergraduate degree from the Indian Institute of Technology and a graduate degree in Finance from The Wharton School at University of Pennsylvania.
Dr. Nandabalan has over two decades of experience across multiple functions in the pharmaceutical and biotechnology industries, including R&D, operations, business development, M&A and In/Out-licensing. He has garnered a deep understanding of market trends impacting the global healthcare environment, the pharma value chain, the current unmet medical needs, and in applying novel technologies to solve these needs. Over the course of his career he has generated significant revenue and shareholder value by completing deals with key industry players such as Pfizer, J&J, AstraZeneca, Pharmacia, BMS, Biogen Idec, Millennium, Merck KGaA, Organon, Sankyo, and Otsuka. He has 12 issued patents and published in leading journals such as Cell and Science. He holds a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, India and was a Post-Doctoral Fellow at the University of Kentucky and Yale University.
Leslie Calman has been CEO of Engineering World Health since 2013. EWH is an international
organization that inspires, educates, and empowers the biomedical engineering community to improve
health care delivery in the developing world. EWH has created programs in a number of countries,
including Honduras, Rwanda, Cambodia, and Nigeria, to train local biomedical engineering technicians to
international standards. In 2018, EHW’s Summer Institute will send 190 engineering students from the
U.S., Australia and Europe to countries in Africa, Asia and Latin America, where they will work in under-
resourced hospitals, installing and fixing vital medical equipment. EWH has 50 university chapters
around the world and sponsors a design competition focused on the needs of low-resource countries.
Leslie previously held positions as Executive Director of Mautner Project: The National Lesbian Health
Organization; VP for External Relations at the International Center for Research on Women; and Exec
VP at NOW Legal Defense and Education Fund.
From 1983 to 1998 she taught political science at Barnard College, Columbia University, and served as
Director of the Barnard Center for Research on Women. She has published two books on social
movements in India.
Mark Gardner is the Chief Executive Officer of OmniSeq Precision Medicine Technology and a member of our Board of Directors. Prior to joining OmniSeq, Mark spent over twelve years in various executive roles at Thermo Fisher Scientific (previously Life Technologies). Most recently, Mark was the Vice President and General Manager of the Ion Torrent business unit at Thermo Fisher. Prior to Thermo Fisher, Mark was a Six Sigma Master Black Belt at General Electric, an entrepreneur at two start-up companies, a management consultant at McKinsey and Company, and a Navy Pilot. Mark is responsible for financing the company, and managing the executive team.
Mark earned an MBA in Finance with Palmer Scholar Distinction from the Wharton School of Business, an MA in National Security Studies from Georgetown University, and a BS with Distinction from the US Naval Academy
Mark Schoenberg, MD is a native of Philadelphia, PA. He graduated from The Johns Burroughs School in St. Louis. MO in 1975. He received his BA in Russian from Yale in 1980 and an MD from The University of Texas in 1986. After completing the residency in General Surgery and Urology at The University of Pennsylvania in 1992, Dr. Schoenberg served as a fellow in Urologic Oncology at Johns Hopkins from 1992-1994. He joined the faculty of The James Buchanan Brady Urological Institute at Hopkins and served there from 1994 until 2014. During a twenty-year career in The Brady Institute of Urology Dr. Schoenberg focused his research and clinical practice on the treatment of patients with urothelial cancer. While at Hopkins he was appointed The Bernard Schwartz Distinguished Professor and Director of Urologic Oncology. In 2014, Dr. Schoenberg was named University Professor and Chair of Urology at The Albert Einstein College of Medicine and The Montefiore Medical Center in Bronx, NY.
Dr. Schoenberg has been an active clinical investigator throughout his career, serving as the national Principal Investigator for NCI-funded research on novel biomarker diagnostic technology; he has also worked as a consultant to major pharmaceutical manufacturers as well as start-up companies seeking to introduce new devices and drugs into the urologic armamentarium. Between 2008-2010, Dr. Schoenberg led clinical investigation for a first-in-man program sponsored by Tengion, Inc. (Philadelphia, PA), a company focused on regenerative medicine technology applied to urinary tract reconstruction. From 2009 until 2014, Dr. Schoenberg served as consulting Chief Medical Officer for SonoCare Medical (Charlotte, NC), a privately held device manufacturer developing image-guided therapeutics for the treatment of prostate cancer. In 2017, Dr. Schoenberg became the Chief Medical Officer of Urogen Pharma, Inc. (Nasdaq: URGN), a clinical stage biotechnology company focused on the development of non-surgical therapeutics for urologic conditions including overactive bladder and urologic cancer.
Dr. Schoenberg is an active contributor to the peer-reviewed literature in urologic oncology having published over 180 scientific articles. He has contributed to Campbell’s Urology (2008) and is a co-Editor of The Texbook of Bladder Cancer (2006), Bladder Cancer (2015) and Management of Urologic Cancer (2017).
Matthew B. Klein, MD, MS, FACS is CEO and Chief Medical Officer of BioElectron Technology Corporation, a biotechnology company located in Mountain View, CA.. Dr. Klein completed his undergraduate degree at University of Pennsylvania where he graduated summa cum laude and phi beta kappa, and received his medical degree from Yale University. Prior to joining BioElectron, Dr. Klein was the Auth-Washington Research Foundation Chair of Restorative Burn Surgery at the University of Washington. He has authored over 90 peer-reviewed publications and 15 book chapters related to his areas of expertise including wound healing, inflammation, epidemiology and public health. He is also Clinical Associate Professor (Affiliate) of surgery at Stanford University.
Matt co-founded Veeva Systems in 2007 and has been instrumental in building the company into a global market leader, recognized for product excellence and superior customer success. After holding various roles during the company's growth, Matt is responsible today for strategy, alliances and business development, and is a key executive contact for many of Veeva's customers.
Before founding Veeva, Matt held various executive roles at small healthcare technology companies in product management, marketing and business development. Prior to that, Matt was the General Manager of the Pharmaceuticals & Biotechnology division at Siebel Systems, which has since been acquired by Oracle. At Siebel, he was responsible for market leading applications in Pharma CRM and clinical trial management. In 2007, Matt was named to the PharmaVOICE 100, which recognizes the 100 most influential people in the life sciences industry.
Matt currently serves on the Advisory Board at Crossix, an innovator in the healthcare analytics arena. Matt received his MBA from the Harvard Business School, with honors, and his B.A. in Economics from Yale University, cum laude.
Co-Founder / Business Lead
Max Perelman leads business operations at Biomeme. Prior to founding Biomeme 5 years ago, Max spent 15 years in a range of industries, including: environmental consulting and green building technology, eCommerce and enterprise systems development, and management consulting. After launching his career in San Francisco, Max lived in Asia for almost a decade, leading projects in Hong Kong, Beijing, Bangkok, and Tokyo. He has a BA from Cornell University and an MBA/MAIEP from the Monterey Institute of International Studies.
Together with my co-founder Noelle Mullin, PhD, I founded Prellis Biologics, Inc in October of 2016 with the goal of reverse engineering a high-power low-toxicity laser used in tissue imaging to 3D print human organs and tissues.
I am a passionate research scientist with cross-disciplinary experience in Immunology, Chemistry, Biophysics, Molecular Biology, and Protein engineering. I am a specialist (>15 years) in 2-photon imaging of immune responses, with international experience (Belgium) and a strong collaborative publication record. I have independently designed experimental protocols, and developed novel methods of data analysis, interpretation of lymphocyte interactions in influenza infection, autoimmune disease, and asthma.
During my graduate work and first post-doctoral position I developed and implemented multiple procedures for live animal and in situ tissue imaging. Many of these were detailed in an invited Cold Spring Harbor Protocols book chapter as well as in early content for the Journal of Visualized Experiments (JoVE).
Additionally I have worked extensively in microscope build, maintenance, small part prototype design/build side-by-side with Dr. Ian Parker who built the first video-rate two-photon microscope for the purpose of imaging in biological tissues.
American Association of Immunologists
European Respiratory Society
Women in Bio, San Francisco Chapter
Specialties: Immunoimaging, Immunology, Teaching, Laboratory Teaching, Science Writing and manuscript editing, Experiment Design and Implementation, Project Leader/Manager, Grant Writing/Review, Educational Writing, Consulting
Mr. Prilutsky is the Chief Operating Officer at the Jersey City Medical Center, a member of the RWJBarnabas Health. Mr. Prilutsky is an experienced healthcare executive with exceptional Management and Leadership skills and has demonstrated results operating in a complex service environment, maintaining and improving existing services, as well as designing, implementing, and marketing large and small scale growth initiatives to enable mission goals of his organization.
Executive experienced in licensing, developing, and commercializing technologies for the vaccines, diagnostics and pharmaceutical marketplace. Strong record in product development and R&D.
Specialties: Particular expertise in:
• Start-up environments and R&D pipeline development
• Valuations and licensing
• Project management of cross-divisional teams
• cGMP environment and regulatory issues
• Assay development for cancer diagnostics and high throughput screening
Niven R. Narain is Co-founder, President & CEO of Berg, a Boston-based biopharma company driving the next generation of drugs and diagnostics by combining patient-driven biology and AI to unravel actionable disease insight. He has overseen development of Berg’s clinical stage assets and pipeline and forged strategic partners with industry, academia, and US and UK governments. Narain is most passionate about improving patient care and enabling increased access to innovative medicines to improved healthcare outcomes. Narain is an industry thought leader on precision medicine and drug development, frequently speaking at The Economist, Bloomberg, Financial Times, and Aspen Ideas meetings in addition to being featured on CNN, BBC, CNBC, Forbes, Fox Business, and the Wall Street Journal. He is inventor of Berg’s flagship Interrogative Biology®, platform that created and guided a deep pipeline of products in oncology, diabetes, and CNS diseases, namely BPM 31510 in Phase 2 trials for cancer. Narain speaks at many international meetings on medicine and technology and his research has been published in Nature Medicine and Cell among others with leading collaborators from academia, NIH, and DoD. He serves on the NASA/Gene Lab Steering Committee and works closely with DoD leadership on breast and prostate cancer initiatives. Narain is an inventor on a patent portfolio of over 550 pending patent applications and over 100 issued patents in the US and internationally, covering multiple disease areas and AI-based technologies. He received his BS/BA in Biochemistry and Philosophy from St. John’s University, NY, obtained PhD training in cancer biology and performed clinical dermatology research at the University of Miami Miller School of Medicine where he served as Director of Cutaneous Oncology Research before moving to Boston. Niven is a recipient of the Sylvester Cancer Center’s Zubrod Prize, an NIH/NIDDK Award of Excellence and was named to the Boston Business Journal top 40 leaders under 40 in 2014. Narain remains active in leadership and community outreach, having served as a mentor to many high school, college, and graduate/medical students in the Intel, Upward Bound, and NIH Howard Hughes Medical Internship programs. He serves as a St. John’s University Boston Chapter alumni advisor and is an active member of the Trinity Church Boston.
Paul Black serves as Allscripts Chief Executive Officer. Paul was appointed CEO in December 2012 after having served on Allscripts Board of Directors for eight months. As Chief Executive Officer, Paul leads the direction of the company and its global commitment to delivering an Open, Connected Community of HealthTM.
Prior to joining Allscripts, Paul spent more than 13 years with Cerner Corporation in various executive positions, retiring as Cerner’s Chief Operating Officer in 2007. During his tenure with Cerner, he helped build the company into a market leader in healthcare information technology with more than $1.5 billion in annual revenue. Prior to Cerner, Paul spent 12 years with IBM Corporation in a variety of leadership positions in sales, product marketing and professional services.
Paul has held positions on multiple private company and non-profit boards of directors. The businesses ranged from healthcare information technology and healthcare services to software and SaaS-based consumer Internet marketing. Paul’s leadership experience on those boards includes serving as director, chairman and executive Chairman. Paul has also provided investment advice to several private equity firms on both coasts.
He is currently Immediate Past Chairman of Truman Medical Centers, as well as an Officer of the Corporation. Truman Medical Centers is a 400-bed safety net academic hospital in Kansas City. Paul earned a Bachelor of Science degree from Iowa State University and a Master of Business Administration from the University of Iowa. He is married with two children and enjoys running, travel and coaching youth sports.
PAVAN CHERUVU, M.D., was born in the US to parents who had emigrated from South India and are naturalized US citizens.
Pavan completed his BSE degrees in biomedical engineering and electrical engineering at Duke University, followed by an MSc degree in computer science at Oxford University, where he was a Rhodes Scholar. Pavan attained his MD in 2009 at Harvard Medical School and the HST program at MIT. He then completed a residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco
Pavan has worked with multiple healthcare-focused startup companies in Boston and the San Francisco Bay Area. He was previously a junior engagement manager at McKinsey & Company.
Pavan is marrried to Deepu Madduri and they live in New York City with their daughter Sofia.
Dr. Phillip Chan is the CEO and President of CytoSorbents Corporation. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the $80M NJTC Venture Fund, one of the top performing and largest early stage investors in the greater New York region. He was responsible for numerous investments in therapeutics, medical devices and diagnostics. Dr. Chan also co-founded Andrew Technologies, a venture-backed medical device company commercializing its FDA approved HydraSolve™ advanced lipoplasty system in the U.S. Dr. Chan received Board-certification in internal medicine, having completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. Dr. Chan received his MD/PhD from Yale University School of Medicine and his BS in cell and molecular biology from Cornell University. In 2012, Dr. Chan was named an Ernst & Young New Jersey Entrepreneur-of-the-Year finalist.
Dr. Richard Park is board-certified in emergency medicine and completed his medical studies at
Albert Einstein College of Medicine in New York. Dr. Park studied emergency medicine in the
Long Island Jewish Medical Center's residency program, where he served as chief resident. He
then worked as the Associate Program Director of the residency program in NS-LIJ's
emergency department and was awarded the Teaching Attending of the Year Award by his
residents in 2003, 2004, 2005 and 2006. Dr. Park was recognized as an expert educator,
receiving a system-wide award in 2007. He then taught in the "Teach the Teacher" fellowship
Dr. Park is the author and co-editor- in-chief of McGraw-Hill's Intensive Review of Emergency
Medicine. He also educates both residents and attending physicians as the co-director of the
NS-LIJ's Manhattan Board Review for Emergency Medicine. Dr. Park holds expertise in all
facets of urgent care delivery and operation. His unparalleled education combined with his
vision for delivering highly accessible, top-quality medical care has made CityMD the top urgent
care in the NY metro area. Dr. Park lives on Long Island with his wife and two children.
Over 15 years of expertise in the area of pharmaco-epidemiologic research, clinical epidemiology, health services research, and clinical trials research. Disease areas of particular interest include chronic diseases with a focus on cardiovascular, diabetes, and obesity. Have expertise in both FDA and EU regulatory procedures and requirements as well as global pharmacovigilance. A visionary with forward thinking problem solving skills with a flexible and can do spirit.
Specialties: QUALIFICATION HIGHLIGHTS
Medical Affairs Organizational Development,
Expert Oral & Written Communication,
Clinical Utility and Market Opportunity Assessment,
Health Outcomes Research,
Clinical Trial Design/Execution,
Patient Reported Outcomes,
EU and FDA Regulatory
Roberta Lipson is CEO and founder of United Family Healthcare (UFH). She has over 30 years of
experience as a pioneer in the healthcare industry in China. She originally co-founded United Family
Healthcare’s predecessor company Chindex in 1981, expanding the business from China’s top medical
equipment distribution company into China’s first and largest foreign-invested healthcare system. After
almost two decades, UFH has established itself with hospitals and clinics in Beijing, Shanghai,
Guangzhou, Wuxi, Tianjin, Qingdao, and Nanjing as the provider of choice for those seeking premium,
personalized healthcare. United Family Healthcare was rated in 2016 as “The Most Trusted Healthcare
Brand of China” by the Chinese Business Journal.
Ms.Lipson is an active leader in the business community in Beijing, having served as a director of the
U.S. China Business Council, as well as 4 successive terms on the Board of Governors of the American
Chamber of Commerce in China (AmCham), and as Co-Chair of the AmCham Healthcare Forum. She
also chairs the Board of the United Foundation for China’s Health (UFCH), and is a co- founder of
Beijing’s Jewish Community, Kehillat Beijing. Because of her outstanding contribution in China, Roberta
Lipson received “The Great Wall Friendship Reward”, the highest honor that Beijing government gives to
foreign experts in Beijing. In 2014 Roberta was honored by AMCHAM as the inaugural recipient of the
China Pioneer Award. She was named as a “Top 10 Business Leader of China” by Sina.com in 2015,
and earlier she led the company to win the U.S. State Department ACE Award for Corporate Excellence.
Ms. Lipson holds a BA from Brandeis University and an MBA from Columbia University.
Ron Cohen, M.D. is President, CEO and founder of Acorda Therapeutics, Inc., a public biotechnology company developing therapies for disorders of the nervous system, including multiple sclerosis, Parkinson’s disease and migraine. Dr. Cohen previously was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation uses. He serves as a Director on the Board of Directors of VBL Therapeutics. He previously served as a Director on the Board of Dyax Corp. until its acquisition in 2016. He also previously served as Chair of the Board of the Biotechnology Innovation Organization (BIO), as Chair of the Emerging Companies Section of the BIO Board, and as Director and Chair of the New York Biotechnology Association (NYBA). Dr. Cohen is a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service.
Acorda Therapeutics has been recognized as one of the Best Companies to Work for in New York State seven years in a row (2011-2017), among the Fortune 100 Best Medium-Size Workplaces the U.S. (2017), and among the Fortune 100 Best Workplaces for Women (2016-2017), Millennials (2017) and Baby Boomers (2017).
Dr. Cohen is a recipient of the NY CEO Lifetime Achievement Award and the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region. He was named Neuroinvestment’s CEO of the Year and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” Dr. Cohen received the Burke Award from Burke Rehabilitation Hospital for his contributions to helping people with disabilities gain independence. He has been recognized by the New York Biotechnology Association as the NYBA “The Cures Start Here” Business Leader of the Year, by the Westchester County Association as its Leadership Award recipient, by Life Science Leader Magazine as True Life Science Leader of the year, by PR Week/MM&M as one of the Health Influencer 50, and by PharmaVOICE Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry.
Dr. Cohen received his B.A. degree with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed a residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine.
Burke Award: https://www.youtube.com/watch?v=WUjyMXwlrkc
I am Biotech series: https://www.youtube.com/watch?v=k_HNDhQodbQ
Acorda web site: http://www.acorda.com/
Sally is the chief visionary, growth officer, insurance geek, and cheerleader at Wellthie. She spends most of her time listening to customers, envisioning new ideas, and building the best team. She envisions a future world where purchasing insurance is a satisfying and confident experience.
Prior to starting Wellthie, Sally spent close to a decade as an executive at Anthem BlueCross BlueShield where she led product development and launched large enterprise initiatives across the country. With a builder’s DNA, Sally spent the first decade of her career wearing business development, marketing, and product hats at successful start-ups like Medscape and another insurance start-up Healthmarkets.
Sally received her MBA from the Wharton School’s Health Care Management program where is an active alumna and mentor. She received her B.S. in Management magna cum laude from the Stern School of Business of New York University.
She is the proud mother of two strong daughters from whom she derives endless inspiration.
Mr. Sam Santhosh is an entrepreneur with over 25 years of experience in initiating and running
successful businesses. Sam is an investor and mentor for many companies and is currently a
board member at Impelsys Inc, New York, ePay Healthcare, San Francisco, SciGenom Labs,
Cochin, Emerge Ventures, Singapore and the Centre for Commercialization of Antibodies
(CCAB) Toronto, Canada.
Prior to this Sam was the CEO and Managing Director of California Software Limited (Calsoft)
from 1992-2012. He founded Calsoft in 1992 and under Sam’s vision Calsoft rapidly grew from a
niche player in the Silicon Valley to a global player with over 1200 employees and presence in 8
countries. Sam took Calsoft public and listed the company in the Indian Stock Exchanges. From
2004 to 2009, Sam focused on inorganic growth through eight acquisitions including companies
in U.S, UK, Japan and India. Post 2009, Sam oversaw the sale of the Calsoft group companies
to different buyers across the world. Sam holds a degree in Mechanical Engineering and an MBA
from IIM Calcutta. He is based in San Francisco and visits India every alternate month.
Scott Topper is currently VP of Clinical Operations at Color, a leading population health genomics company based in San Francisco. Dr. Topper’s focus is on improving health outcomes through innovative delivery of accurate genetic information at scale. At Color, he oversees clinical, delivery and lab operations and laboratory research and development. Prior to Color, Scott served as the head of clinical genomics at Invitae, leading the development of the clinical service from early startup through its current position as the leading player in genetic diagnostics. Prior to his transition to industry, Dr. Topper was a licensed clinical molecular geneticist at the University of Chicago.
Stanley M. Bergman
Since 1989, Stanley M. Bergman has been Chairman of the Board and CEO of Henry Schein, Inc., a Fortune 500® company and the world's largest provider of health care products and services to office-based dental, animal health, and medical practitioners, with more than 22,000 Team Schein Members and operations or affiliates in 34 countries. Henry Schein is a member of the S&P 500® and Nasdaq 100® indexes. In 2017, the Company's sales reached a record $12.5 billion. Henry Schein has been a Fortune World's Most Admired Company for 17 consecutive years.
Mr. Bergman serves as a board member or advisor for numerous institutions including New York University College of Dentistry; the University of Pennsylvania School of Dental Medicine; the Columbia University Medical Center; University of the People; Hebrew University; Tel Aviv University; the University of the Witwatersrand Fund; The World Economic Forum’s Health Care Governors; the Business Council for International Understanding, the Japan Society and the Metropolitan Opera. Mr. Bergman is an honorary member of the American Dental Association and the Alpha Omega Dental Fraternity. Stan is the recipient of the Ellis Island Medal of Honor; the CR Magazine Corporate Responsibility Lifetime Achievement Award; the 2017 CEO of the year award by Chief Executive Magazine; Honorary Doctorates from The University of the Witwatersrand, Hofstra University, A.T. Still University’s Arizona School of Dentistry and Oral Health, Case Western Reserve University and Farmingdale State College (SUNY); and Honorary Fellowship from King’s College London - Dental Institute and the International College of Dentists.
Stan and Marion Bergman and their family are active supporters of organizations fostering the arts, higher education, cultural diversity and grassroots health care and sustainable entrepreneurial economic development initiatives in the United States, Africa and other developing regions of the world.
Mr. Bergman is a graduate of The University of the Witwatersrand in South Africa, and is a South African Chartered Accountant and a NYS Certified Public Accountant (CPA).
Serving as the Senior Healthcare Executive for Spectrum Health Post-Acute Health, Steven Nemerson is responsible for a $300 million enterprise encompassing all aspects of healthcare beyond the acute inpatient hospital and clinic. Responsible, along with his team, for thousands of daily patient encounters, Dr. Nemerson has driven the integration of multiple disparate components of the System into the highest performing operation of its type.
As Chief Executive Officer of Health System Analytics, a consulting firm helping clinical and commercial healthcare organizations to enhance their performance and identify new revenue opportunities, Dr. Nemerson continues innovative and entrepreneurial work.
In the past, as Chief Medical Officer for the Aurora Health Care Southeast Market, Dr. Nemerson was responsible for clinical quality, physician alignment and business strategy. And as CMO and Vice President of Medical Affairs for Vanguard West Suburban Medical Center and Vanguard Westlake Hospital, Dr. Nemerson drove those hospitals and their medical staffs to reduce expenses, increase efficiencies and improve outcomes
Similarly, as Medical Executive Director and CMO of Lower Bucks Hospital, Dr. Nemerson’s team reduced patient length of stay, enhanced clinical revenues, and improved clinical performance scores returning the hospital to financial stability. And as Director of Performance Improvement, Patient Safety, and Utilization Management for Temple University Children’s Medical Center, Dr. Nemerson was instrumental in that center’s exceeding national benchmarks while at the same time reducing their cost of care.
Dr. Nemerson has an MBA from the Temple University, a Medical Degree from Pennsylvania State University, a Masters of Science in Biomedical Engineering from Johns Hopkins University, and a Bachelor of Science in Biomedical Engineering from Brown University. He is board-certified in Administrative Medicine, Pediatrics and Pediatric Critical Care Medicine.
Steve Reed is the Founder, President, and CEO of the Infectious Disease Research Institute (IDRI), based in Seattle, USA. His academic appointments include Professor of Medicine at Cornell University Medical College in New York and Research Professor of Pathobiology at the University of Washington. He serves on several editorial review committees, has served as a member of the Tropical Medicine Review Board of the National Institutes of Health, and is a member of the Vaccine Development Steering Committee of the World Health Organization.
Dr. Reed received a PhD in Microbiology and Immunology from the University of Montana in 1979. That year he was appointed as Scientist of the National Institute of Amazon Research in Manaus, Brazil, where he directed research on tropical diseases. Dr. Reed joined Cornell University Medical College in 1980 as Assistant Professor of Medicine, continuing to work in Brazil as manager of the Cornell-Bahia program in International Medicine. He joined the Seattle Biomedical Research Institute in 1984 where he worked until founding IDRI in 1993. In 1994 he co-founded Corixa Corporation (which was later sold to GlaxoSmithKline, GSK) where he served as Chief Scientific Officer until leaving in 2004. In 2008 Dr. Reed co-founded Immune Design Corp. where he served as CEO until 2011.
Dr. Reed’s research interests have focused on the immunology of intracellular infections, and on the development of vaccines and diagnostics for both cancer and infectious diseases. In partnership with GSK, he led the team that developed the first defined tuberculosis vaccine to advance to clinical trials. He also developed the first defined vaccines for leishmaniasis, as well as the K39-based diagnostic tests currently licensed for leishmaniasis. He has more than 375 original publications, 35 book chapters and reviews, and 105 issued patents on diagnostics, vaccines, and therapeutics of infectious diseases and cancer.
Pharmaceutical executive with extensive global drug development and commercialization experience in large global multinational pharmaceutical, mid-size, and small biotech settings. Experience spans all phases of the drug development, including in-line brand leadership. Product Development Team Leader for a number of approved (Orbactiv, Natpara, Clozaril, Fanapt, and Valdoxan) and late-stage products including orphan drugs and devices. Strategic, results-oriented executive with experience across multiple therapeutic areas including Endocrine Disorders, Anti-infectives/Antivirals, Central Nervous System Disorders (Schizophrenia, Bipolar Disorders, Generalized Anxiety Disorders, Major Depression, Migraine, Anesthesia), and Women’s Health (Contraception, Infertility, Osteoporosis). Extensive international experience spanning development and commercialization. Strong proven track record with demonstrated strategic and execution excellence. Instrumental in the establishment and build-out of world-class Global Development Organizations in emerging biotech settings. Graduate of the inaugural class of Women in Bio’s Boardroom Ready Program.
Dr. Yael Schwartz is a Massachusetts life science executive and serial
entrepreneur with a broad record of achievement amassed during 30+
years in pharmaceutical drug discovery and development.
Following her stint at Sepracor (Sunovion) where she worked on teams that
developed Lunesta® for the treatment of insomnia, Brovana® for Chronic
Obstructive Pulmonary Disease management, Xopenex® for the treatment
of bronchoconstriction in asthma, she founded two companies, Hygeia
Therapeutics and Canterbury Laboratories that were focused on woman’s
health and dermatology. Both companies were acquired and taken public
by RestorGenex (RESX). At RestorGenex she was the only woman on the
Board of Directors and was the Executive VP of Preclinical Development.
In late 2015, following substantive disagreements pertaining to leadership
and the overall direction of RestorGenex she submitted her resignation and
flexed her entrepreneurial muscle again by founding Or-Genix
Therapeutics, a company developing medical dermatology and aesthetic
dermatology topical products for acne, aging skin, hair and mucous
membranes. Under her leadership, Or-Genix raised more capital, filed
new patents and entered into several commercial licensing deals.
Yael received her Bachelors degree from Salem State University, and
entered the Master’s degree program in Pharmacology/Toxicology at
Northeastern University. In 1991, Yael received her Ph.D. with honors in
Human Endocrine Physiology from a joint program between the WPI
Department of Biology/Biotechnology, Worcester, MA and the University of
Massachusetts Medical School, Department of Physiology, Worcester, MA.
In 2014, she was nominated, by the Town of Holden’s Fire Chief, for the
Madeline Amy Sweeney Award for Civilian Bravery for successfully
rescuing and performing CPR on two children who nearly died in a
backyard pool accident.
In 2015, Yael was recognized as a “Trail Blazer” and was featured in the
WPI alumni magazine (Winter Edition) in an article titled “Skin Deep”.
8 Canterbury Lane
Holden, MA 01520 774-242- 1135
Yael is the recipient of The Boston Business Journal Biotech Innovation All-
For the past 10 years, Yael has served on the Board of Trustees of
Massachusetts Biomedical Initiatives (MBI). She is co-founder of a non-
profit organization for executive women in the healthcare sector, the
NEWISE Club (New England Women in Science Executive’s Club), Boston,
MA. She is an Honorary Member of Phi Lambda Sigma, The Pharmacy
Leadership Society, for her teaching and mentorship activities at
Massachusetts College of Pharmacy and Health Sciences.
For the two years she has been spending up to 10 hours a week at WPI in
the Foisie School of Business as the Coleman Entrepreneur-in- Residence.
In that capacity, she has provided inspiration, reality-checks and guidance
for several new start-up companies.
Yael believes that true success is defined by how you handle the highs and
lows of life, the difficult and the easy, while maintaining a sense of humor
and purpose throughout.
Loving the challenges of entrepreneurship, she has no desire to retire,
considers golf the most boring thing since white bread and prefers
spending time with her husband, family and friends, hiking with her two
dogs, Kaif and Bella, and competitive pistol shooting.
Yaron Werber, M.D., MBA, is the chief business and financial officer, treasurer, and was
previously secretary of Ovid Therapeutics. In his role at Ovid, Dr. Werber is responsible for all
financial planning and reporting, business development, strategy, operations/IT and investor
and public relations. Since joining Ovid, Dr. Werber led negotiations to secure an innovative
partnership with Takeda Pharmaceuticals, not only expanding Ovid’s pipeline but also
pioneering a novel approach for partnering the focused expertise of small biotech with big
pharma. This deal that has been chosen by Scrip as a finalist for the 2017 Best Partnership
Alliance Award. In addition, Dr. Werber facilitated a $75 million Series B round in 2015 and
Ovid’s $75 million IPO in 2017.
Prior to joining Ovid, Dr. Werber worked at Citigroup Global Markets Inc. from 2004 to 2015,
where he most recently served as a managing director and the head of U.S. healthcare and
biotech equity research teams. During his tenure at Citi, Dr. Werber and his team conducted indepth
analyses of life science companies at all stages of development, ranging from successful,
profitable companies to recently public and privately held companies. At Citi, Dr. Werber was
awarded several accolades for performance, was highly ranked by the Institutional Investor
Magazine survey, and voted among the top five analysts in the biotech sector by the “Best on
the Street Survey” of the Wall Street Journal.
Previously, Dr. Werber was a senior biotech analyst and vice president at SG Cowen Securities
Corporation. In 2017, Dr. Werber was selected as an Emerging Pharma Leader by
Pharmaceutical Executive magazine.
Dr. Werber earned his B.S. in Biology from Tufts University, cum laude, and a combined
M.D./MBA degree from Tufts University School of Medicine where he was a Terner Scholar.
Zachary Hornby brings over ten years of life sciences business experience to Ignyta. Prior to joining Ignyta, Zach was senior director of business development at Fate Therapeutics where he was responsible for pharmaceutical partnerships and non-dilutive funding. Zach has also served in various business and commercial roles at Halozyme Therapeutics, Neurocrine Biosciences and TKT (now Shire Human Genetic Therapies), and was a life sciences consultant at L.E.K. Consulting. Zach holds B.S. and M.S. degrees in biology, with a concentration in neuroscience, from Stanford University and an M.B.A. from Harvard Business School.
Senior physician executive responsible for advancing value focused strategies throughout the Carolinas HealthCare System. Transitioning the delivery system toward a consumer-oriented, value based model of care.
Carolinas HealthCare System, one of the nation's leading and most innovative healthcare organizations, provides a full spectrum of healthcare and wellness programs. The diverse network of more than 900 care locations includes hospitals, healthcare pavilions, physician practices, destination centers, surgical and rehabilitation centers, home health agencies, nursing homes, and hospice and palliative care. Carolinas HealthCare System works to improve and enhance the overall health and well-being of its communities through high quality patient care, education and research programs, and a variety of collaborative partnerships and initiatives.
William R. Wagner has extensive experience in structuring and negotiating secured and unsecured credit facilities on behalf of corporate borrowers, private equity firms, portfolio companies, agent banks, financial institutions, and specialty lenders. He has substantial experience advising healthcare, life sciences, pharmaceutical and biotech companies on their most important transactions. In addition, he focuses his practice on loan workouts, financial restructurings, special situations, and distressed investments. He regularly counsels hedge funds, investment and commercial banks, asset managers, and strategic investors on legal issues related to the purchase and sale of distressed assets and strategic investments in distressed companies. Mr. Wagner also regularly advises startups and early-stage emerging companies on financing techniques and investment opportunities. He has extensive experience in both foreign and domestic markets.
He is a frequent speaker on loan market developments, financial legislation, bankruptcy issues, and the restructuring process.
Brett R. Friedman has experience advising a broad spectrum of clients on a variety of complex transactional, enforcement and regulatory matters within the health care industry. His clients include hospitals, managed care plans, pharmacy and dental benefit managers, pharmaceutical and device manufacturers and community-based providers of care to persons with mental illness and developmental disabilities. He routinely advises clients in responding to government investigations and audits concerning potential violations of health care fraud and abuse laws; maintaining regulatory compliance; and structuring innovative arrangements involving the development of integrated health care delivery networks in connection with value-based payment models.
Dr. Ilyayev Received his training from NY Methodist Hospital and Memorial Sloan Kettering Hospital in Manhattan. He is in the forefront of continuing education, always looking for new medical breakthroughs to help his patients.
Dr. Ilyayev started his HouseCall MD practice right after completing his residency. He realized that there were elderly homebound patients who have not seen a doctor in years. He also realized that by seeing these patients in their home, this would decrease the rate of hospitalizations thereby doing his role in decreasing our national healthcare related costs.
Dr. Erik Ilyayev’s positive attitude and self-motivation is the reason he is booked one month in advance.
Dr. Esteban Pombo-Villar, is Chief Executive Officer of TargImmune Therapeutics, a biopharmaceutical company focused on the development of novel immuno-oncology therapeutics, based in Basel, Switzerland. Previously he was Chief Operations Officer (COO) for Oxford BioTherapeutics, and a Member of their Boards of Directors. Prior to joining Oxford BioTherapeutics, Dr. Pombo-Villar was at Novartis and Sandoz for over 23 years, the last 12 years engaged in Business Development and Alliance Management, and as Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR). Prior to that he served in several roles as medicinal chemist in the Neuroscience research group. He obtained a PhD, MSc and BSc in organic chemistry from the University of Warwick (UK), was a visiting researcher at the University of Newcastle upon Tyne (UK), and completed postdoctoral studies at the ETH in Zurich. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, member of several scientific societies and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US). A native of Bogotá, Colombia, he lives in Switzerland since 1986.
Lawrence Obstfeld is CEO of Image Navigation which has developed the FDA-approved IGI system for CT-navigated oral-maxillofacial surgery and the DentSim - augmented reality dental simulator. Also a founder of BetaGene, Inc. and Gladius Pharmaceuticals.
Marjorie Kaufman, CFA is a multifaceted marketing and finance executive with over 30 years experience in investment banking and asset management. Marjorie has raised over $5 billion in capital for private investment funds over the course of her career with firms such as Bankers Trust, Prudential Securities, J&W Seligman, KingdonCapital and Guggenheim Partners. She has also acquired expertise in healthcare and biotech corporate development through direct investment and close collaboration with firm executives on growth and monetization strategies in companies such as Inspiren, Mobile ODT, Sprout Pharmaceuticals and Undercover Colors. Marjorie currently serves as Vice Chair of FWA’s Directorship and Coporate Governance Committee, Chairman of the Board for Undercover Colors, Inc., Advisory Board Member for the Bio Capital Impact Fund, Director and Investment Committee Chair for Westchester Land Trust and Chairman of Hilltop Cares Foundation. Marjorie holds a BA magna cum laude in economics and anthropology from the University of Pennsylvania and an MBA in finance from the University of Chicago Booth School of Business. In 1996 Marjorie was awarded the Chartered Financial Analyst designation. In 2010 she was named one of the 50 Leading Women in Hedge Funds by the Hedge Fund Journal. An accomplished photographer, Marjorie posts images at her website www.marjoriekaufman.com.
Dr. Longmire is a Stanford-trained physician-entrepreneur dedicated to transforming healthcare through innovation. Dr. Longmire has a background in epigenetics, novel diagnostics, and imaging. She has published over 20 peer reviewed articles and holds patents in machine learning as applied to mobile health applications. Dr. Longmire's vision is to enable health technology to be as adaptive, seamless, and integrated as the human body.
Dr. Peter Kash Ed.D/MBA has been in the field of biotechnology for over almost 30 years helping fund more than a dozen biopharmaceutical companies several with FDA approvals. Currently, he is Managing Director at Castle Hill Capital Partners and Vice-Chairman of TargImmune Therapeutics AG.
Besides a BS in Management Science and an MBA in Finance he also holds a Doctorate in Education from the Azrieli School of Yeshiva University. He has served as an adjunct Professor of Entrepreneurship at the Wharton School of Business, and has been a Visiting Professor at Nihon University in Tokyo Japan and in 2015 as a Visiting Professor at Hebrew University in Jerusalem. He has authored several books distributed in more than 30 countries, his most recent release is Take Two Tablets Medicine from the Bible.
Rami founded Telesofia Medical (MyOp.md), combining his passions to medicine and technology.
He has over 20 years of experience in the Internet industry. He started his career in 1997 at ICQ (formerly Mirabilis, acquired by AOL in 1998, for US$407 million) in various roles including Director of Web Operations. Since 2001, he helped several companies and start-ups with product development, launching and marketing in the online world. As VP Operations at Novawind, he provided Hands-On marketing, business development, and innovation management services for leading companies.
Rami also holds a medical doctor degree from the Tel Aviv University and worked at the Vascular Surgery department in Tel-Aviv Sourasky (Ichilov) Medical Center and Assaf Harofeh Medical Center.
Risa leads the GE Ventures, New Business Creation team. The team has started companies in healthcare and other industries including: Evidation Health, Vineti, Avitas Systems, Current powered by GE, and Menlo Microsystems. Risa joined the GE Ventures team from Kleiner Perkins Caufield & Byers where she was a partner for 10 years. While at Kleiner Perkins Caufield & Byers, Risa incubated several companies and was the founding CEO of two. Risa has invested in and held board director or observer roles in over a dozen healthcare companies including: Corthera (acquired by Novartis), Epizyme (NASDAQ: EPZM), Foundation Medicine (NASDAQ:FMI), Ilex Oncology (acquired by Genzyme), Orexigen (NASDAQ:OREX), Pacific Biosciences (NASDAQ:PACB), Triangle Pharmaceuticals (acquired by Gilead), Trius (acquired by Cubist), and Veracyte (NASDAQ:VCYT). Risa holds a degree in genetics and development with distinction from the University of Illinois, a Ph.D. in immunology from the University of Chicago, and was a member of the second class of Kauffman Fellows.
Rodney Dean Reider serves as President and CEO of Saint
Alphonsus Health System, a multi-hospital and clinically-
integrated healthcare system serving Southwestern Idaho
and Eastern Oregon. Mr. Reider provides vision and
leadership in the transformation of the organization to a
people-centered Health System. Under Mr. Reider's
leadership the health system places the people they serve at
the center of every decision as they work to improve quality,
the experience of care, and the health of our communities.
Previously, Mr. Reider served in healthcare leadership as Vice President, Aurora St.
Luke's Medical Center in Milwaukee, WI; President and CEO, Community Health
Systems/University of Pennsylvania Health System in Philadelphia, PA; as well as
several other President and CEO positions prior. Mr. Reider received his MBA at Loma
Linda University; his Masters of Science at Cal Poly Pomona Harrison; and he has a
Master of Arts and Doctorate from Harrison Middleton University. He has studied as an
international scholar studying healthcare and business in both Western Australia and
Salzburg, Austria. He is a Fellow of the American College of Healthcare Executives.
Locally, Mr. Reider is involved in critical community strategies, such as the City of
Boise's Housing First Initiative, which will transition the chronically homeless to a stable
housing environment. Saint Alphonsus is a major funder of the project and will be
providing health care to the residents once the project is operational.
Mr. Reider has also been inducted into the 124 th Fighter Wing of the Idaho National
Guard as an honorary commander. In that position, he is supporting the important role
the National Guard has throughout the State of Idaho and the local community. Saint
Alphonsus works with to support and train as well as employ numerous Idaho National
Guard members in our area hospitals and clinics.
In 2017, Mr. Reider was selected as one of 10 "CEO's of Influence" in the business and
non-profit sectors in Idaho by the Idaho Business Review.
Ronni P. Solomon, Esq., serves as executive vice president and general counsel at ECRI Institute, an independent, non-profit organization that focuses on improving the safety, quality and cost effectiveness of healthcare. The Institute brings the discipline of applied scientific research to discover which medical procedures, devices, drugs, and processes are best. Solomon has developed and led many innovative ECRI Institute initiatives on patient safety and quality that are widely used by thousands of hospitals, health systems, and provider organizations.
Thora Johnson co-chairs Venable's Healthcare Initiative. She provides counsel on regulatory, compliance, tax, and business matters impacting healthcare providers, hospitals, continuing care retirement communities, health insurers, group health plans, pharmaceutical and medical device companies, and digital health companies. She has a broad knowledge of traditional healthcare regulatory matters, including Health Insurance Portability and Accountability Act (HIPAA) privacy, security, and breach notification requirements; state health information privacy laws; Medicare/Medicaid compliance; and federal and state fraud and abuse rules. She has also closely followed, and provided counsel on, healthcare reform through all of its stages of development and continues to track and provide guidance on it as it evolves.
In addition, Thora has extensive experience in health and welfare plan compliance, including the regulatory requirements of the Employee Retirement Income Security Act (ERISA), the Internal Revenue Code, federal and state healthcare coverage continuation laws, the Mental Health Parity and Addiction Equity Act, Genetic Information Nondiscrimination Act, the regulations under the Americans with Disabilities Act (ADA) applicable to employer wellness programs, and the Affordable Care Act (ACA).
Thora is also experienced in employee benefits and executive compensation and nonprofit tax matters.
Viren Mehta, PharmD, MBA, Managing Member, founded and is managing member of Mehta Partners, LLC. His analytical insights on global health care have influenced bio-pharmaceutical strategy and investments worldwide. Educated at the University of Southern California (Doctor of Pharmacy) and UCLA (MBA in international finance and marketing), he has worked with senior BioPharma leaders and investment managers for over 30 years. Gather Health is Viren's new initiative to empower patients while enhancing physician productivity. Gather Health brings together providers (physicians, nurses, dietician, exercise therapist and others) and patients' social network (other patients, friends and family), enabling patient to get real-time and active resources and motivation from this team that improves outcomes. Physicians are able to see more patients due to the efficiencies fostered by the GH triage engine. Gather Health is headquartered in Hong Kong, with operations in Beijing, Mumbai and New York. Viren's biopharma strategic advisory work focuses on refining the business model to expand global healthcare access, and to help the bio-pharmaceutical industry succeed globally. Viren’s philanthropic work in ecology and education through viram foundation includes an active board role with Project Hope (Washington DC) and the Venice Family Clinic (Los Angeles, CA). Viren began with Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly. Now known as Mehta Partners, with a 30-year record, Viren continues to focus on helping refine investment strategy to achieve superior growth while enhancing access to healthcare innovations.
Connecting the Pharma & Healthcare industry with compliant innovation has been Febbo’s trademark in over 18 years of leading health service & technology companies. In 1999, he co-founded MedPanel, a market intelligence and communication provider to the biomedical & medical device industries. When Febbo sold it in 2007 to Merriman Capital, he held dual roles as COO of the bank and CEO of Digital Capital Network which he launched pioneering digital compliance & transparency in the financial industry.
Febbo is also founder of Plexuus, an early stage payment processing platform for medical professionals with Sunshine Act-related activities. Currently, he holds the position of CEO at OptimizeRX and continues to discover, innovate and connect both products and people to meaningful experiences to improve health outcomes. Febbo has most recently joined MIT linQ as a faculty member. LinQ is a new collaborative initiative focused on increasing the potential of innovative research to benefit society and the economy. linQ’s portfolio of international innovation programs demonstrates a new paradigm for technology research and training. Thus far, Febbo has participated in two of these programs, IMPACT and Idea2 global.
Febbo holds a Bachelor of Arts in International Studies from Dickinson College, in Pennsylvania and serves on the board of The United Nations of Greater Boston, a non-profit focused on building global citizens within inner-city schools in Massachusetts.
William R. Wagner has extensive experience in structuring and negotiating secured and unsecured credit facilities on behalf of corporate borrowers, private equity firms, portfolio companies, agent banks, financial institutions, and specialty lenders. He has substantial experience advising healthcare, life sciences, pharmaceutical and biotech companies on their most important transactions. In addition, he focuses his practice on loan workouts, financial restructurings, special situations, and distressed investments. He regularly counsels hedge funds, investment and commercial banks, asset managers, and strategic investors on legal issues related to the purchase and sale of distressed assets and strategic investments in distressed companies. Mr. Wagner also regularly advises startups and early-stage emerging companies on financing techniques and investment opportunities. He has extensive experience in both foreign and domestic markets.
He is a frequent speaker on loan market developments, financial legislation, bankruptcy issues, and the restructuring process.
Jacob Plotsker is a Director at HighPoint Solutions, an IQVIA company, where he helps life science and healthcare clients develop strategy, establish best practice frameworks, and implement technology to drive client performance on a global scale.
Mr. Plotsker has more than 25 years of U.S. and international marketing, product launch, finance and commercial operations experience in the pharmaceutical industry. His therapeutic experience includes Women’s Health, Anti-infectives, Urology, and Anesthesia/Pain.
He was formerly President of Cambridge Sage Group, LLC, a strategic life sciences consultancy, where he consulted for clients in numerous areas, including corporate strategy, strategic planning, marketing, product launch planning, business development, and lifecycle management.
He was Head of Commercialization for ODH, Inc. (an Otsuka company), a healthcare solutions company that leverages big data, technology and clinical expertise to transform the delivery and economics of healthcare.
Prior to ODH, he was responsible for strategy and lifecycle management for Bayer’s women’s health division, as well as the identification and evaluation of new commercial opportunities and technologies. Mr. Plotsker was Head of Marketing and Commercial Operations for Teva Women’s Health and additionally has held senior commercial, marketing and finance positions with Pfizer Inc., Organon International and Schering-Plough Corporation.
Mr. Plotsker currently serves on the board of directors of Emisphere Technologies, Inc., a publicly traded drug delivery technology company and Bioceptive, Inc., a private women’s health company. He previously served on the strategic advisory board of Provectus Biopharmaceuticals, a publicly traded company focused on oncology and dermatology. He also served on the board of directors of Sharsheret, a 501(c)3 national not-for-profit organization providing support and resources to young women living with breast and ovarian cancer, and was president from 2009-2012.
Mr. Plotsker holds a Bachelor of Arts in accounting and information systems from Queens College of the City University of New York; a Master of Business Administration in marketing and finance from New York University Stern School of Business; and completed the Executive Development Program in general management at the University of Chicago Booth School of Business.